You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,668,929


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,668,929 protect, and when does it expire?

Patent 8,668,929 protects XARTEMIS XR and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 8,668,929
Title:Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
Inventor(s): Han; Chien-Hsuan (Sunnyvale, CA), Hou; Sui Yuen Eddie (Foster City, CA), Reid; Monica L. (San Mateo, CA)
Assignee: Depomed, Inc. (Newark, CA)
Application Number:13/529,960
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,668,929
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,668,929

Introduction

United States Patent 8,668,929, hereafter referred to as the '929 patent, is a significant intellectual property asset that has been involved in various legal and commercial activities. To analyze its scope and claims, we need to delve into the patent's details, its legal context, and the broader patent landscape.

Patent Overview

The '929 patent is one of several patents mentioned in a legal dispute involving Mallinckrodt Inc. and Mallinckrodt LLC against Actavis Laboratories FL, Inc.[2].

Patent Claims and Scope

Claim Structure

Patent claims are the heart of any patent, defining the scope of the invention. The '929 patent, like other patents, would have a set of claims that outline what is novel and non-obvious about the invention. These claims can be independent or dependent, with dependent claims building upon the independent claims[3].

Claim Analysis

To understand the scope of the '929 patent, one would need to analyze each claim carefully. Here are some key aspects to consider:

  • Independent Claims: These define the broadest scope of the invention and are typically more general.
  • Dependent Claims: These narrow down the invention by adding specific limitations to the independent claims.
  • Claim Language: The clarity and specificity of the claim language are crucial. Broadly worded claims can lead to ambiguity and potential legal issues[4].

Legal Context and Litigation

Patent Infringement

The '929 patent was part of a lawsuit where Mallinckrodt Inc. and Mallinckrodt LLC alleged that Actavis Laboratories FL, Inc. had infringed upon several patents, including the '929 patent. The lawsuit involved claims under 35 U.S.C. ยง 271(e)(2)(A), which pertains to infringement related to the submission of an Abbreviated New Drug Application (ANDA)[2].

Court Decisions

The court proceedings involved multiple stipulated orders dismissing various claims and counterclaims. For instance, on May 25, 2016, the court entered a stipulated order dismissing all claims and counterclaims related to several patents, including the '929 patent[2].

Patent Quality and Examination

USPTO Initiatives

The United States Patent and Trademark Office (USPTO) has been working to improve patent quality, which is relevant to understanding the validity and enforceability of patents like the '929 patent. The USPTO's Enhanced Patent Quality Initiative aims to ensure that patents meet statutory requirements for novelty, clarity, and non-obviousness[4].

Examination Process

The examination process for patents involves a thorough review to ensure that the claims are clear, concise, and exact. The USPTO has implemented measures to improve the clarity of patent applications, although it has decided not to require additional tools like glossaries of key terms due to stakeholder feedback[4].

Global Patent Landscape

Global Dossier

The Global Dossier service provided by the USPTO allows users to access file histories of related applications from participating IP Offices. This can be useful in understanding the global patent family and the status of related applications, including those related to the '929 patent[1].

Patent Families

Understanding the patent family of the '929 patent involves looking at all related applications filed at participating IP Offices. This includes examining the dossier, classification, and citation data for these applications[1].

Economic and Statistical Insights

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. This dataset can offer insights into the scope and trends of patent claims, which can be applied to understanding the '929 patent[3].

Stakeholder Perspectives

Industry Experts

Industry experts and legal practitioners often provide valuable insights into the patent landscape. For example, the Administrative Conference of the United States (ACUS) study on a potential small claims patent court involved consultations with a wide range of stakeholders, including academic experts and legal practitioners. Such perspectives can help in understanding the practical implications of patent claims and scope[5].

Key Takeaways

  • Patent Claims: The scope of the '929 patent is defined by its claims, which must be clear, concise, and exact.
  • Legal Context: The patent has been involved in litigation, highlighting the importance of clear claims and thorough examination.
  • Global Landscape: Understanding the global patent family and using services like Global Dossier can provide comprehensive insights.
  • Patent Quality: The USPTO's initiatives to improve patent quality are crucial for ensuring the validity and enforceability of patents.

FAQs

What is the significance of clear and concise claim language in patents?

Clear and concise claim language is essential to avoid ambiguity and ensure that the patent can be upheld if challenged in a lawsuit. Broadly worded claims can lead to difficulties in examination and potential legal issues[4].

How does the Global Dossier service help in understanding patent families?

The Global Dossier service allows users to access file histories of related applications from participating IP Offices, providing a comprehensive view of the patent family, including classification, citation data, and office actions[1].

What are the key initiatives by the USPTO to improve patent quality?

The USPTO has initiated several measures, including defining a consistent definition of patent quality, reassessing examination time, analyzing the effects of incentives, and considering the use of claim clarity tools[4].

What is the role of the Patent Claims Research Dataset in understanding patent scope?

The dataset provides detailed information on claims from U.S. patents and applications, offering insights into claim structure, dependency relationships, and statistical trends, which can be applied to understanding the scope of specific patents like the '929 patent[3].

Why is stakeholder feedback important in patent policy?

Stakeholder feedback is crucial as it reflects the practical implications and needs of various stakeholders, including patent applicants, examiners, and legal practitioners. This feedback helps in shaping policies and tools that improve the patent system[5].

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. PATUNAS LAW LLC - Litigation Documents: https://insight.rpxcorp.com/litigation_documents/12463585
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. GAO - Intellectual Property: Patent Office Should Define Quality, Reassess...: https://www.gao.gov/products/gao-16-490
  5. ACUS - U.S. Patent Small Claims Court: https://www.acus.gov/research-projects/us-patent-small-claims-court

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,668,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ⤷  Subscribe ⤷  Subscribe MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,668,929

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009223061 ⤷  Subscribe
Canada 2720108 ⤷  Subscribe
China 102105136 ⤷  Subscribe
European Patent Office 2262484 ⤷  Subscribe
Hong Kong 1152469 ⤷  Subscribe
Japan 2011513499 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.